RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.
Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, Makarova N, Goyal N, Guo W, Zappe D, Desai AS; KARDIA-1 Study Group.
Bakris GL, et al.
JAMA. 2024 Mar 5;331(9):740-749. doi: 10.1001/jama.2024.0728.
JAMA. 2024.
PMID: 38363577
Free PMC article.
MAIN OUTCOMES AND MEASURES: The primary end point was between-group difference in least-squares mean (LSM) change from baseline to month 3 in 24-hour mean ambulatory SBP. RESULTS: Of 394 randomized patients, 377 (302 receiving zilebesiran and 75 receiving placebo) comprise …
MAIN OUTCOMES AND MEASURES: The primary end point was between-group difference in least-squares mean (LSM) change from baseline to month 3 i …